TSCAN THERAPEUTICS, INC. (TCRX)

Every figure this model derived for TCRX, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 2,159,000 PaymentsToAcquirePropertyPlantAndEquipment 2026-06-30
cash 115,103,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 104,403,000 AssetsCurrent 2026-06-30
current liabilities 30,964,000 LiabilitiesCurrent 2026-06-30
equity 69,019,000 StockholdersEquity 2026-06-30
interest expense 2,789,000 InterestExpense 2026-06-30
ocf -116,280,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 7,111,000 RevenueFromContractWithCustomerExcludingAssessedTax 2026-06-30
sbc 9,841,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up TCRX on one particular measure came for.

RatioValue
cash operating margin-1516.23
current ratio3.44
current ratio reported3.37
deferred revenue growth-92.39
dilution pct15.89
fcf margin-1665.57
growth cv1.48
interest cover-43.22
operating margin-1695.15
revenue growth2.15
revenue growth per share-11.86
rule of 40-1692.99
sbc pct revenue138.39

What to be careful about

What this model itself distrusts about TCRX's figures. Written by the derivation as it ran, not added afterwards.